



PRESS RELEASE

The information was submitted for publication on 20 January 2017 at 10.30.

Presentation of Probi's Q4 report 2016

Probi's report for the fourth quarter 2016 will be published on Tuesday, 24 January at 8.00 a.m.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Peter Nählstedt and CFO Niklas Brandt will present and comment on the report. The presentation and presentation material can be obtained via www.probi.se or <https://wonderland.videosync.fi/probi-bokslutskommunike-2016>

The presentation can also be followed via a telephone conference on the following telephone number:
Sweden: 08-56 64 26 91
UK: +44 20 30 08 98 04
US: +18557532235

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the addresses given above following the presentation.

FOR MORE INFORMATION, PLEASE CONTACT:

Peter Nählstedt, CEO, Probi, telephone +46 46 286 89 23, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, telephone +46 46 286 89 26, e-mail: niklas.brandt@probi.se

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi's products are available to consumers in more than 30 countries worldwide. Probi's customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 216 in 2015. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has approximately 4,400 shareholders. For more information, please visit www.probi.se.